Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Helius Medical Technologies (HSDT – Research Report) yesterday and set a price target of $1.00. The company’s shares closed yesterday at $0.19.
According to TipRanks, Vendetti is an analyst with an average return of -3.2% and a 32.06% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Biolase, Pulse Biosciences, and ReShape Lifesciences.
Helius Medical Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $1.00.
See today’s best-performing stocks on TipRanks >>
Based on Helius Medical Technologies’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $244 thousand and a GAAP net loss of $1.65 million. In comparison, last year the company earned a revenue of $119 thousand and had a GAAP net loss of $3.81 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Helius Medical Technologies, Inc. operates as a medical technology company, which engages in the development of products for the treatment of neurological symptoms caused by disease and trauma. It focuses on licensing and acquiring platform technologies that amplify the brain’s ability to heal itself. The company was founded in 2014 and is headquartered in Newtown, PA.
Read More on HSDT:
- Helius Medical reports Q2 EPS (6c), consensus (12c)
- Is HSDT a Buy, Before Earnings?
- Helius Medical adds Montefiore Medical to PoNSTEP
- Helius Medical Technologies, Inc. Announces Participation of Montefiore Medical Center in its PoNS® Therapeutic Experience Program
- Helius Medical Technologies, Inc. to Release Second Quarter 2023 Financial Results on August 10, 2023
